Cytosorbents Corp (CTSO)

• Market cap: $40.8M
• 1 day: -8.13%
• 5 days: -20.04%
• 1 month: 1.56%
• 3 months: 1.58%
• 6 months: -28.49%
• Year to date: -0.87%
• 1 year: -42.47%
• 5 years: -93.08%
• 10 years: -83.11%
• Sector: Healthcare
• Industry: Medical Devices

About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Employees: 149